Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China and internationally. It operates through Medical Device Products, Orthopedic Products, Pharma Packaging Products, Interventional Products, Blood Management Products, and Others segments. The company's medical device pro… Read more
Shandong Weigao Group Medical Polymer Company Limited (UK2) - Total Assets
Latest total assets as of June 2025: €36.14 Billion EUR
Based on the latest financial reports, Shandong Weigao Group Medical Polymer Company Limited (UK2) holds total assets worth €36.14 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Weigao Group Medical Polymer Company Limited - Total Assets Trend (2013–2024)
This chart illustrates how Shandong Weigao Group Medical Polymer Company Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Weigao Group Medical Polymer Company Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Weigao Group Medical Polymer Company Limited's total assets of €36.14 Billion consist of 55.9% current assets and 44.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 22.4% |
| Accounts Receivable | €6.08 Billion | 17.5% |
| Inventory | €2.53 Billion | 7.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.30 Billion | 3.8% |
| Goodwill | €3.83 Billion | 11.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Shandong Weigao Group Medical Polymer Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Weigao Group Medical Polymer Company Limited's current assets represent 55.9% of total assets in 2024, an increase from 55.4% in 2013.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2024, down from 26.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 17.5% of total assets.
Shandong Weigao Group Medical Polymer Company Limited Competitors by Total Assets
Key competitors of Shandong Weigao Group Medical Polymer Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Shandong Weigao Group Medical Polymer Company Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shandong Weigao Group Medical Polymer Company Limited generates 0.38x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Shandong Weigao Group Medical Polymer Company Limited generates $5.95 in net profit.
Shandong Weigao Group Medical Polymer Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.73 | 3.28 | 3.22 |
| Quick Ratio | 3.32 | 2.89 | 2.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €15.15 Billion | € 13.58 Billion | € 8.59 Billion |
Shandong Weigao Group Medical Polymer Company Limited - Advanced Valuation Insights
This section examines the relationship between Shandong Weigao Group Medical Polymer Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.90 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 3.2% |
| Total Assets | €34.76 Billion |
| Market Capitalization | $1.36 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Weigao Group Medical Polymer Company Limited's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shandong Weigao Group Medical Polymer Company Limited's assets grew by 3.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shandong Weigao Group Medical Polymer Company Limited (2013–2024)
The table below shows the annual total assets of Shandong Weigao Group Medical Polymer Company Limited from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €34.76 Billion | +3.24% |
| 2023-12-31 | €33.67 Billion | +1.43% |
| 2022-12-31 | €33.20 Billion | +9.32% |
| 2021-12-31 | €30.37 Billion | +11.05% |
| 2020-12-31 | €27.34 Billion | +3.87% |
| 2019-12-31 | €26.33 Billion | +9.75% |
| 2018-12-31 | €23.99 Billion | +42.92% |
| 2017-12-31 | €16.78 Billion | +6.52% |
| 2016-12-31 | €15.76 Billion | +16.55% |
| 2015-12-31 | €13.52 Billion | +12.01% |
| 2014-12-31 | €12.07 Billion | +6.93% |
| 2013-12-31 | €11.29 Billion | -- |